S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

Mirati Therapeutics Stock Forecast, Price & News

-0.76 (-0.56%)
(As of 11/29/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
416,110 shs
Average Volume
493,599 shs
Market Capitalization
$7.05 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Mirati Therapeutics logo

About Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm's products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.


Mirati Therapeutics (NASDAQ:MRTX) Trading 4.2% Higher
November 19, 2021 |  americanbankingnews.com
Mirati Therapeutics (NASDAQ:MRTX) Sees Strong Trading Volume
November 11, 2021 |  americanbankingnews.com
Mirati Therapeutics (NASDAQ:MRTX) Shares Down 7.3%
November 10, 2021 |  americanbankingnews.com
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
October 7, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.40 million
Book Value
$20.92 per share


Net Income
$-357.94 million
Pretax Margin




Free Float
Market Cap
$7.05 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.86 out of 5 stars

Medical Sector

755th out of 1,392 stocks

Pharmaceutical Preparations Industry

360th out of 670 stocks

Analyst Opinion: 4.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics
or view top-rated stocks.

How has Mirati Therapeutics' stock been impacted by Coronavirus?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRTX stock has increased by 75.8% and is now trading at $136.00.
View which stocks have been most impacted by COVID-19

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Mirati Therapeutics

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($2.87) by $1.32. The biotechnology company had revenue of $71.79 million for the quarter, compared to the consensus estimate of $1.41 million. The firm's revenue for the quarter was up 528.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.96) EPS.
View Mirati Therapeutics' earnings history

What price target have analysts set for MRTX?

12 analysts have issued twelve-month price objectives for Mirati Therapeutics' shares. Their forecasts range from $173.00 to $285.00. On average, they anticipate Mirati Therapeutics' share price to reach $211.40 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price.
View analysts' price targets for Mirati Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • David D. Meek, Chief Executive Officer & Director
  • Charles M. Baum, President, Director & Head-Research & Development (LinkedIn Profile)
  • Daniel R. Faga, Executive VP, Chief Operating & Financial Officer
  • James G. Christensen, Chief Scientific Officer & Executive VP (LinkedIn Profile)
  • Philip Roberts, Senior Vice President-Technical Operations

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.64%), BlackRock Inc. (5.15%), RTW Investments LP (2.88%), Franklin Resources Inc. (2.47%), Artal Group S.A. (2.32%) and Janus Henderson Group PLC (1.93%). Company insiders that own Mirati Therapeutics stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie Christensen, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, BlackRock Inc., Janus Henderson Group PLC, Clough Capital Partners L P, Morgan Stanley, Cubist Systematic Strategies LLC, Integral Health Asset Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Jamie Christensen, Ltd Braslyn, Maria E Martinez, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics
or view top insider-selling stocks.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Artal Group S.A., Wellington Management Group LLP, Eagle Asset Management Inc., Lord Abbett & CO. LLC, Caption Management LLC, Jennison Associates LLC, and International Biotechnology Trust PLC.
View insider buying and selling activity for Mirati Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $136.00.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $7.05 billion and generates $13.40 million in revenue each year. The biotechnology company earns $-357.94 million in net income (profit) each year or ($9.53) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 200 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

Where are Mirati Therapeutics' headquarters?

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 332-3410 or via email at [email protected].

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.